Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 19.13.
Forward PE Ratio (19.13) = Close Price ($105.52) / Consensus Forward EPS ($5.52)
FORWARD PE RATIO
19.13
SECTOR MEDIAN · HEALTHCARE
19.90
median of 78 covered companies
CURRENT VS SECTOR MEDIAN
-3.85%
vs the sector median at left
Abbott Laboratories
Market Cap
$182.59B
Forward PE Ratio
19.13
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Abbott Laboratories (ABT) | $182.59B | 19.13 |
| Gilead Sciences, Inc. (GILD)vs › | $182.06B | N/A |
| Novo Nordisk A/S (NVO)vs › | $200.54B | N/A |
| Pfizer Inc. (PFE)vs › | $158.39B | 9.34 |
| Amgen Inc. (AMGN)vs › | $212.20B | 17.04 |
| Danaher Corporation (DHR)vs › | $144.25B | 24.14 |
| Thermo Fisher Scientific Inc. (TMO)vs › | $224.09B | 24.44 |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $134.24B | 29.13 |
| Bristol-Myers Squibb Company (BMY)vs › | $132.14B | 9.34 |
| Intuitive Surgical, Inc. (ISRG)vs › | $123.70B | 32.42 |
Trailing P/E
33.9
reported TTM EPS
Forward P/E
19.1
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $5.52 implies +77.5% EPS growth vs the reported trailing $3.11.
At today's $105.52 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $5.52 | $5.48 – $5.57 | 17 | 19.1x |
| 2027-12-31 | $6.06 | $6.01 – $6.18 | 17 | 17.4x |
| 2028-12-31 | $6.72 | $4.47 – $8.01 | 11 | 15.7x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute